Newsroom

Key releases are ad hoc announcements pursuant to SIX Swiss Exchange Art. 53 LR

Latest press release
View all

Latest press releases and news stories

Go to news archive

Featured News Article

GALDERMA'S RESPONSE TO AESTHETIC IMPACT OF MEDICATION-DRIVEN WEIGHT LOSS 

Medication driven weight loss report cover 2 940x434

Discover key insights from the first international consensus guidelines in the full report.

ACCESS THE REPORT
Galderma Annual Reports
Annual Report 2024
Annual Review 2023
ANNUAL REVIEW 2022
ANNUAL REVIEW 2021

MEDIA TOOLKIT: ATOPIC DERMATITIS 

Atopic Dermatitis Newsroom

Access materials for additional information about the burden of atopic dermatitis.

READ MORE

MEDIA TOOLKIT: PRURIGO NODULARIS

Prurigo Nodularis Newsroom

Access materials for additional information about the burden of prurigo nodularis.

READ MORE

MEDIA TOOLKIT: SENSITIVE SKIN AND MODERN LIFESTYLES

Sensitive skin medi factsheet

Galderma’s scientific response to a growing dermatological challenge.

READ MORE

MEDIA TOOLKIT: MEDICATION-DRIVEN WEIGHT LOSS

MDWL Media factsheet

Understanding the aesthetic impacts of significant and rapid weight loss.

READ MORE

GET IN TOUCH WITH

CHRISTIAN MARCOUX
Chief Communications Officer
christian.marcoux@galderma.com
+41 76 315 26 50
RICHARD HARBINSON
Corporate Communications Director
richard.harbinson@galderma.com
+41 76 210 60 62

JEFF SMITH
Head of U.S. Communications
jeffrey.smith@galderma.com
+1 (682) 401-8428

EMIL IVANOV
Head of Strategy, IR and ESG
emil.ivanov@galderma.com
JESSICA COHEN
Investor Relations & Strategy Director
jessica.cohen@galderma.com
+41 21 642 76 43

SEE U.S. PRESS RELEASES

Cetaphil Oil to Foam
25.08.2025
Press release
Galderma introduces Cetaphil Nourishing Oil to Foam Cleanser, a breakthrough in hydrating cleansing for sensitive skin
U.S. release
17.06.2025
Press release
Galderma establishes new U.S. headquarters in Miami and strengthens regional leadership
U.S. release
Scratch Resistance
22.04.2025
Press release
Galderma launches "Scratch Resistance" campaign to validate the physical and emotional burdens of atopic dermatitis
U.S. release